Anxiety

Anxiety Disorders: Primary Care Impact and Early Recognition

Anxiety disorders are among the most common psychiatric conditions seen in primary care, with a lifetime prevalence approaching 30% in the U.S. adult population.^[1] Family Nurse Practitioners (FNPs) frequently encounter patients presenting with excessive worry, panic attacks, or somatic complaints that mask underlying anxiety. Early recognition, accurate diagnosis, and evidence-based management improve quality of life and reduce the risk of chronic disability. This guide covers the high-yield concepts FNPs must master for certification exams and clinical practice.

Classifying Anxiety Disorders: Panic, Phobia, and GAD

• Anxiety – An unpleasant emotional state characterized by subjective feelings of tension, apprehension, nervousness, and worry, often accompanied by autonomic arousal. It is a normal response to threat but becomes a disorder when it is excessive, persistent, and impairs function.^[2]
• Fear – A cognitive response to a real, perceived, or anticipated danger, often triggering a “fight-or-flight” response. In contrast, anxiety involves prolonged anticipation of future threat.
• Panic attack – A sudden surge of intense fear or discomfort that peaks within minutes and includes at least 4 of 13 symptoms (e.g., palpitations, sweating, trembling, shortness of breath, chest pain, nausea, dizziness, chills, paresthesias, depersonalization, fear of losing control or dying).^[2]
• Generalized Anxiety Disorder (GAD) – Excessive anxiety and worry occurring more days than not for at least 6 months, about multiple events or activities, with difficulty controlling the worry and at least three associated symptoms (restlessness, fatigue, poor concentration, irritability, muscle tension, sleep disturbance).^[2]
• Panic Disorder – Recurrent unexpected panic attacks followed by at least one month of persistent concern about having another attack, worry about the implications of the attack, or a significant change in behavior related to the attacks.^[2]
• Social Anxiety Disorder (Social Phobia) – Marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others. The fear is out of proportion to the actual threat and leads to avoidance or distress.^[2]
• Agoraphobia – Fear or anxiety about being in situations where escape might be difficult or help unavailable in the event of panic-like symptoms. Typical situations include public transportation, open spaces, enclosed spaces, crowds, or being outside the home alone.^[2]
• Specific Phobia – Marked fear or anxiety about a specific object or situation (e.g., flying, heights, animals, receiving an injection). The phobic stimulus almost always provokes immediate fear, leading to avoidance or enduring it with intense distress.^[2]

Neurobiology and Diagnostic Screening Steps

Neurobiology of Anxiety

Anxiety disorders involve dysregulation of the amygdala (fear center), prefrontal cortex (inhibitory control), and locus coeruleus (norepinephrine system). Key neurotransmitters include serotonin (5-HT), norepinephrine, and GABA (gamma-aminobutyric acid). Decreased GABA activity and altered serotonin receptor function are implicated in excessive fear responses.^[3]

Screening and Initial Assessment

1. Universal screening – The USPSTF recommends screening for anxiety in adults 18–64 years, including pregnant and postpartum persons, using validated instruments such as the GAD-7 or Edinburgh Postnatal Depression Scale (EPDS) with anxiety subscale.^[4]
2. History – Explore onset, duration, triggers, frequency, and impact on daily function. Assess for panic attacks, avoidance behaviors, and comorbid depression or substance use.
3. Medical evaluation – Rule out underlying medical causes such as hyperthyroidism, electrolyte disturbances, cardiac arrhythmias, hypoglycemia, or stimulant use (e.g., caffeine, cocaine). Obtain TSH, basic metabolic panel, and ECG if indicated.
4. Suicide risk assessment – Ask directly about suicidal thoughts, plans, and intent. Use the PHQ-9 item 9 or the Columbia-Suicide Severity Rating Scale (C-SSRS).^[5]
5. Diagnostic criteria – Apply DSM-5 criteria to differentiate among anxiety disorders (GAD, panic disorder, social anxiety, agoraphobia, specific phobia) and rule out other conditions (e.g., PTSD, OCD, depression with anxiety features).^[2]

Anxiety Symptom Clusters and Associated Conditions

• Psychological symptoms: Excessive worry, irritability, restlessness, difficulty concentrating, muscle tension, sleep disturbances (insomnia), and a sense of impending doom.
• Physical symptoms: Palpitations, tachycardia, diaphoresis, trembling, shortness of breath, chest tightness, nausea, dizziness, paresthesias, hot flashes, and frequent urination.
• Behavioral signs: Avoidance of feared situations, procrastination, clinging to others, or safety-seeking behaviors (e.g., always carrying a phone or medication).
• Panic attack features: Abrupt onset, peak within 10 minutes, and at least 4 of the 13 DSM-5 panic attack symptoms. Panic attacks can be expected (cue-triggered) or unexpected (spontaneous).^[2]
• Comorbidities: Major depressive disorder, substance use disorders (especially alcohol, benzodiazepines, cannabis), irritable bowel syndrome, chronic pain, and cardiovascular disease.^[1]

Anxiety Disorder Diagnostic Criteria and Medical Differential

Differential diagnoses to exclude before diagnosing an anxiety disorder:

• Medical: hyperthyroidism, pheochromocytoma, COPD, asthma, cardiac arrhythmias, hypoglycemia, vestibular disorders, drug intoxication/withdrawal.
• Psychiatric: major depressive disorder (often includes anxiety), posttraumatic stress disorder, obsessive-compulsive disorder, bipolar disorder (agitated states), and substance-induced anxiety.

Evidence-Based Anxiety Management: Therapy, Medication, and Lifestyle

First-Line Psychotherapy

• Cognitive-behavioral therapy (CBT) is the gold standard, focusing on cognitive restructuring (identifying distorted thoughts) and exposure therapy (gradual confrontation of feared stimuli).^[6]
• Alternative options: Acceptance and Commitment Therapy (ACT), mindfulness-based stress reduction (MBSR), and interpersonal therapy (IPT) for comorbid depression.

First-Line Pharmacotherapy

• Selective serotonin reuptake inhibitors (SSRIs): Escitalopram, sertraline, paroxetine, fluoxetine – consider first for GAD, panic disorder, social anxiety, and PTSD. Dosing should start low and be titrated slowly to minimize side effects (initial jitteriness, GI upset).^[7]
• Serotonin-norepinephrine reuptake inhibitors (SNRIs): Duloxetine, venlafaxine XR – effective for GAD and panic disorder. Venlafaxine XR requires blood pressure monitoring due to dose-related hypertension.
• Pregabalin – Approved for GAD in some regions; useful when SSRIs/SNRIs are not tolerated or effective.
• Buspirone – Useful for GAD primarily; less effective for panic disorder. No abuse potential, but requires consistent dosing.

Second-Line and Adjunctive Agents

• Benzodiazepines (e.g., lorazepam, alprazolam, clonazepam) – Provide rapid relief but should generally be reserved for short-term use or crisis management due to risk of tolerance, dependence, cognitive impairment, and falls in older adults.^[8] Avoid as monotherapy in GAD.
• Hydroxyzine – Antihistamine with anxiolytic properties; low abuse potential; can be used PRN or scheduled, but sedation limits long-term use.
• Beta-blockers (propranolol) – Helpful for performance anxiety (e.g., social phobia) but not for generalized anxiety.

Patient Education and Lifestyle Management

• Educate about the nature of anxiety (normalizing symptoms) and the rationale for treatment (both therapy and medication).
• Avoid caffeine, alcohol, stimulants, and over-the-counter decongestants that can worsen anxiety.
• Regular aerobic exercise (30 minutes most days) reduces anxiety symptoms.^[9]
• Good sleep hygiene, relaxation techniques (deep breathing, progressive muscle relaxation), and limiting screen time before bed.
• Teach patients to keep a symptom diary to identify triggers and track response to therapy.

Safety Monitoring and Special Considerations in Anxiety Management

• Suicide risk: Anxiety disorders alone increase suicide risk, especially when comorbid with depression or substance use. Monitor for suicidal ideation at every visit, especially when starting antidepressants (may activate mood).^[5]
• SSRI/SNRI side effects: Serotonin syndrome (rare but serious – fever, rigidity, clonus, confusion); sexual dysfunction; weight gain; hyponatremia (elderly).
• Benzodiazepine risks: Overuse can lead to paradoxical agitation, confusion (especially in elderly), falls, and respiratory depression when combined with opioids. Use caution in patients with COPD, sleep apnea, or substance use history.
• Tapering: Do not abruptly discontinue benzodiazepines or SNRIs (venlafaxine has a very short half-life). Taper slowly over weeks to months to avoid withdrawal syndromes (rebound anxiety, seizures with benzodiazepines).
• Pregnancy: Paroxetine and benzodiazepines are generally avoided in pregnancy. SSRIs (especially sertraline and fluoxetine) are considered relatively safer but must be weighed against risks.
• Monitoring: Check thyroid function and basic labs at baseline; obtain a baseline ECG if using high-dose SNRIs or in patients with cardiac disease.

Essential Exam Concepts and Clinical Pearls for Anxiety

• Memorize the DSM-5 key criteria for GAD, panic disorder, social anxiety, and agoraphobia – especially the duration thresholds (6 months for most except panic disorder’s 1 month of worry).
• Know the first-line pharmacotherapy: SSRIs (escitalopram, sertraline) are preferred for most anxiety disorders; SNRIs are second-line unless contraindicated.
• Differentiate panic disorder from GAD: Panic disorder = recurrent unexpected panic attacks + worry about future attacks; GAD = chronic worry about multiple life domains without panic attacks necessarily.
• Screen for medical causes: Exam questions often test the need to obtain TSH and rule out hyperthyroidism before starting treatment.
• Avoid benzodiazepines as first-line except in acute crisis or while waiting for an SSRI to take effect (2-4 weeks). Be aware of the Beers Criteria cautioning against benzodiazepines in older adults.
• Therapeutic delay: SSRIs may initially increase anxiety (“jitteriness”); counsel patients that improvement occurs after 2-4 weeks. Do not stop early.
• Combined therapy works best: CBT plus pharmacotherapy is superior to either alone for moderate-to-severe anxiety.
• Risk of substance use: Many patients self-medicate with alcohol or marijuana; always screen for comorbid SUD using the AUDIT or DAST-10.
• Pediatric and adolescent considerations: Fluoxetine and sertraline are first-line for pediatric anxiety; CBT is strongly recommended. Be aware of black box warning for increased suicidal ideation – monitor closely.^[10]
• Memory aid for GAD symptoms: “Restless, Easily fatigued, Concentration poor, Irritable, Muscle tension, Sleep disturbance” → RECIMS.

References and Sources

1. National Institute of Mental Health. Any Anxiety Disorder – Lifetime Prevalence Among Adults. 2023. https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013. https://doi.org/10.1176/appi.books.9780890425596
3. Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32(3):549-575. https://doi.org/10.1016/j.psc.2009.05.004
4. U.S. Preventive Services Task Force. Screening for Anxiety in Adults. JAMA. 2023;329(24):2168-2178. https://jamanetwork.com/journals/jama/fullarticle/2806250
5. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health: Mental Health Detailed Tables. Substance Abuse and Mental Health Services Administration; 2021. https://www.samhsa.gov/data/sites/default/files/reports/rpt39441/NSDUHDetailedTabs2021/NSDUHDetailedTabs2021/NSDUHDetailedTabs2021.pdf
6. Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36(5):427-440. https://doi.org/10.1007/s10608-012-9476-1
7. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107. https://doi.org/10.31887/DCNS.2017.19.2/bbandelow
8. American Geriatrics Society. Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. https://doi.org/10.1111/jgs.18372
9. Ströhle A. Physical activity, exercise, depression and anxiety disorders. J Neural Transm. 2009;116(6):777-784. https://doi.org/10.1007/s00702-008-0092-x
10. Hepburn S, Yang J, Arolt V, et al. The efficacy and safety of antidepressants in children and adolescents with anxiety disorders: a systematic review and meta-analysis. J Child Psychol Psychiatry. 2020;61(5):518-530. https://doi.org/10.1111/jcpp.13151